CN111904959A - Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia - Google Patents
Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia Download PDFInfo
- Publication number
- CN111904959A CN111904959A CN202010851711.5A CN202010851711A CN111904959A CN 111904959 A CN111904959 A CN 111904959A CN 202010851711 A CN202010851711 A CN 202010851711A CN 111904959 A CN111904959 A CN 111904959A
- Authority
- CN
- China
- Prior art keywords
- virus
- pharmaceutically acceptable
- acceptable salt
- use according
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides an application of an alpha-L-fucosidase inhibitor deoxyfucose nojirimycin or a pharmaceutically acceptable salt thereof in preparing a medicament for preventing and/or treating infantile viral pneumonia. The deoxyfucose nojirimycin or the pharmaceutically acceptable salt thereof inhibits viral activity, reduces pulmonary index, reduces mortality, prolongs survival time, inhibits inflammatory factor production, and reduces IFN-gamma, TNF-alpha, and IL-6 levels in a subject.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of deoxyfucose nojirimycin (deoxyfucojojirimycin) or pharmaceutically acceptable salt thereof in preparing a medicine for preventing and/or treating infantile pneumonia in a subject.
Background
Infantile pneumonia is a common disease in infants and is a common cause of infant death. Pneumonia is lung inflammation caused by pathogen infection or amniotic fluid and oil inhalation and anaphylactic reaction, and is clinically manifested by fever, cough, shortness of breath, dyspnea, lung rale and the like, the early body temperature is 38-39 ℃, and can also be as high as 40 ℃. In addition to respiratory symptoms, infants may be accompanied by general symptoms such as listlessness, dysphoria, anorexia, diarrhea, etc. Food refusal, milk choking, vomiting and dyspnea are common in small infants. Pathogens causing pediatric pneumonia include bacteria, viruses, mycoplasma, chlamydia, fungi, and the like. Among them, viral pneumonia accounts for a high proportion of infantile pneumonia, and viral infections such as respiratory syncytial virus, adenovirus, influenza virus, parainfluenza virus and the like are the main pathogens causing infantile viral pneumonia. Two or more viruses may be mixed and viral pneumonia may be followed by bacterial infection.
The clinically commonly used medicines for treating infantile pneumonia comprise western antiviral medicines and Chinese patent medicines. Western antiviral drugs are mainly classified into nucleoside antiviral drugs, non-nucleoside antiviral drugs and interferon according to chemical structures. Among them, nucleoside antiviral drugs mainly mimic the structure of natural nucleotides, act competitively on the active center of the enzyme, intercalate into the viral DNA chain being synthesized, and terminate the elongation of the DNA chain, thereby inhibiting viral replication. Clinically commonly used nucleoside antiviral agents include ribavirin, acyclovir, vidarabine, ganciclovir, cidofovir and the like. The non-nucleoside antiviral drug mainly comprises Abidol, which is a non-nucleoside spectrum antiviral drug, and in vivo and in vitro experiments show that the non-nucleoside spectrum antiviral drug has an inhibitory effect on various viruses including influenza virus, human rhinovirus, Coxsackie virus and adenovirus. The abidol inhibits viral action by direct killing of viral and antiviral biosynthesis and the therapeutic index increases with prolonged drug and cellular duration. Interferons are proteins produced by biological cells under the stimulation of viral infection or other acoustic agents, do not act directly on viruses, exert antiviral effects by causing cells to produce certain enzymes and other mechanisms, and have effects on both DNA and RNA viruses. The antiviral western medicine has a plurality of adverse reactions while playing an antiviral role, reversible anemia can be caused by taking the ribavirin with a large dose, and the interferon can cause the patients to have side effects of fever, headache, hypodynamia, reduction of leukocyte level, increase of transaminase and the like. Acyclovir has temporary adverse renal effects, and ganciclovir can reduce the level of white blood cells and platelets. The action mechanism of the traditional Chinese medicine antiviral drug is not clear, the treatment effect is not exact, and a plurality of uncertainties exist. Therefore, there is still a need to develop new drugs for treating infantile viral pneumonia infection in clinic.
Iminosugars are a class of synthetic carbohydrate compounds. They are capable of interfering with glycosyl hydrolases (glycosidases) and glycosyltransferases and possess a number of biological activities including anti-diabetic, anti-insect, plant growth regulating, immunomodulating, anti-cancer and anti-bacterial and viral infections. Among such imino sugar compounds, α -D-glucosidase inhibitors and α -L-fucosidase inhibitors have received much attention. It has been shown that alpha-glucosidase I inhibitors, such as deoxynojirimycin and castanospermine, interfere with the correct glycosylation of HIV viral envelope glycoproteins (such as glycoproteins gp120 and gp41) and have antiretroviral activity. N-butyl deoxynojirimycin is active against Bovine Viral Diarrhea Virus (BVDV) and induces misfolding of the viral envelope protein. In addition, the compound can be used as a novel glycolipid biosynthesis inhibitor and also has the activity of inhibiting human Hepatitis B Virus (HBV). Castanospermine has been found to be active against measles virus in addition to anti-HIV activity, both effects being attributed to abnormal folding of viral glycoproteins. Furthermore, castanospermine interferes with the expression of influenza virus neuraminidase on the cell surface and the correct folding of dengue virus envelope glycoprotein, and has activity against influenza virus and dengue virus. However, the prior art lacks reports of the antiviral activity of alpha-L-fucosidase inhibitors which are structurally similar to alpha-D-glucosidase inhibitors.
The research of the invention shows that the alpha-L-fucosidase inhibitor deoxyfucojirimycin (Deoxfuconojirimycin) has obvious in vitro antiviral activity on common respiratory system virus adenovirus, influenza A virus, influenza B virus, respiratory syncytial virus, coxsackie virus or parainfluenza virus and the like, and further proves the antiviral effect of the fucojirimycin in neonatal mouse pneumonia caused by the influenza A virus through an animal model, thereby completing the invention.
Disclosure of Invention
The invention provides application of deoxyfucose nojirimycin (Deoxyfuconojirimycin) or pharmaceutically acceptable salt thereof in preparing a medicament for preventing and/or treating infantile pneumonia in a subject.
In a specific embodiment, the subject is an infant, and the subject is between 0 and 6 years of age.
In another specific embodiment, the deoxyfucose nojirimycin is present in the form of a pharmaceutically acceptable salt which may be selected, for example, from hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid, preferably deoxyfucose nojirimycin hydrochloride (deoxyfucojirimycin hydrochloride).
According to a particular embodiment of the invention, the pneumonia is caused by a viral infection.
Further, the virus is adenovirus, influenza a virus, influenza b virus, respiratory syncytial virus, coxsackie virus or parainfluenza virus. Preferably, the virus is influenza a virus subtype H1N 1.
According to a particular embodiment of the invention, said deoxyfucose nojirimycin or a pharmaceutically acceptable salt thereof is capable of directly inhibiting viral activity, reducing the pulmonary index, reducing mortality, prolonging survival time of said subject.
Further, the deoxyfucose nojirimycin or the pharmaceutically acceptable salt thereof inhibits inflammatory factor production and reduces IFN-gamma, TNF-alpha and IL-6 levels.
According to a specific embodiment of the present invention, the deoxyfucose nojirimycin or the pharmaceutically acceptable salt thereof is formulated into a pharmaceutical preparation selected from an oral preparation, a parenteral preparation, an inhalation preparation or a topical preparation, with a pharmaceutically acceptable excipient.
Further, the preparation is selected from tablets, capsules, oral liquid, water injection, powder injection, spray, transdermal patches, emulsion and paste.
Advantageous effects
The antiviral activity of the alpha-L-fucosidase inhibitor deoxyfucose nojirimycin on common respiratory viruses which easily cause infantile upper respiratory infection and infantile pneumonia, such as adenovirus, influenza A virus, influenza B virus, respiratory syncytial virus, coxsackie virus or parainfluenza virus, is proved by in vitro antiviral experiments. And an in vivo animal experiment further proves that the deoxyfucose nojirimycin has the treatment effect on pneumonia of a newborn mouse infected by the H1N1 influenza virus, and the result shows that the deoxyfucose nojirimycin can obviously reduce the lung infection index of the newborn mouse with pneumonia, reduce the death rate, prolong the survival time, inhibit the generation of inflammatory factors and reduce the levels of IFN-gamma, TNF-alpha and IL-6.
Detailed Description
The present invention is described in more detail below to facilitate an understanding of the present invention.
Example 1 in vitro antiviral Activity study of deoxyfucose nojirimycin
1. Medicine and reagent
Deoxyfucose nojirimycin hydrochloride (DMF-H) was purchased from Beijing Taize Jia science and technology development Co., Ltd, and ribavirin (ribavirin) was purchased from Jiangxi Hui Ringyao pharmaceutical Co., Ltd. Human embryonic lung cells (MRC-5) were purchased from Wuhan Punuoise Life technologies, Inc. Influenza A H1N1 cell strain (FM/1/47), influenza B virus B, adenovirus (dV7), parainfluenza virus (HVJ) and Respiratory Syncytial Virus (RSV) were purchased from the institute of virology, national academy of preventive medicine.
2. Experimental methods
(1) Determination of the maximum non-toxic concentration of DMF on cells
MRC-5 cells (30 ten thousand/ml) were seeded in 96-well plates at 0.1ml per well, in 5% CO2Culturing in an incubator at 36 ℃ for 24-36H, adding DMF-H with different concentrations after the cells grow into a monolayer, firstly, adding DMF2mM stock solution was prepared in DMSO and then diluted proportionally into 10 concentration gradients of 2mM, 1mM, 500. mu.M, 250. mu.M, 125. mu.M, 62.5. mu.M, 31.25. mu.M, 15.625. mu.M, 7.8125. mu.M, 3.90625. mu.M, 0.1ml per well, 2 wells per concentration, and a blank cell control set. Adding 5% CO2And culturing in an incubator at 60 ℃ for 72 hours, and taking the minimum dilution factor (the highest concentration of the drug which does not generate toxicity on cells) of the drug which does not generate cytopathic effect in 2 holes under the same concentration as the non-toxic limiting dilution factor.
(2) Determination of the inhibitory Effect of DMF on common respiratory viruses
Using the maximum nontoxic concentration as the initial concentration, diluting to 3 concentrations (125. mu.M, 62.5. mu.M and 31.25. mu.M), and ribavirin (5. mu.M) as the positive control, antiviral tests were performed, respectively at 100TCID50The H1N1 type, the B type influenza virus, the parainfluenza virus SPV, the respiratory syncytial virus RSV and the adenovirus AdV7 are mixed evenly, the mixture is taken out after being put into a refrigerator at 4 ℃ for 24 hours, 0.1mL of the mixture of each liquid medicine concentration and the virus is added into a 96-well plate carrying a single-layer MRC-5 cell, two holes are arranged at each concentration, a virus control hole and a cell control hole are arranged at the same time, the mixture is cultured for 72 hours at the temperature of 5% CO2 and 37 ℃, and the cell viability is measured by an MTT method.
3. Results of the experiment
(1) Maximum non-toxic concentration of DMF
The maximum non-toxic concentration of DMF to human embryonic lung cells MRC-5 was determined to be 125. mu.M.
(2) In vitro antiviral action
As can be seen from the results in table 1, DMF has a certain inhibitory effect on H1N1 influenza a virus, influenza B virus, adenovirus (dV7), parainfluenza virus (HVJ), and Respiratory Syncytial Virus (RSV), among which the inhibitory effect on H1N1 influenza a virus is strongest, and is significantly different from the virus control group (p < 0.001).
TABLE 1 OD490 values for the in vitro antiviral action of DMF: (
n＝2)
*p<0.5,**p<0.01,*＊*p<0.001
Example 2 Effect of deoxyfucose nojirimycin on influenza A H1N1 Virus infection of mice
1. Laboratory animal and reagent
ICR mice (SPF/VAF grade) born for 10 days, weighing about 10g, and having no limitation of sex, were purchased from Beijing Wintonlifa laboratory animal technology, Inc. Deoxyfucose nojirimycin hydrochloride (DMF-H) was purchased from Beijing Taize Jia industries, science and technology development, Inc. Mouse gamma interferon (IFN-gamma) enzyme-linked reaction kit, product of U.S. R & D company; mouse tumor necrosis factor alpha (TNF-alpha) enzyme-linked reaction kit, products of U.S. R & D company; IL-6 test kit, a product of Nanjing Kangkui Co. Tamiflu (oseltamivir phosphate capsules), shanghai roche pharmaceutical limited.
2. Experimental methods
The mice were randomly divided into 6 groups of 20 mice each, namely a normal control group, a model control group, a positive control group (tamiflu 27.5mg/kg), a DHF high dose group (80mg/kg), a medium dose group (40mg/kg), a low dose group (20mg/kg) and a combined drug group (tamiflu 13.75mg/kg + DHF20 mg/kg). During the test, the medicines in each group are prepared into 20 mL/kg according to the equal volume-1And (4) administration. Except for the normal control group, mice were lightly anesthetized with ether and 15 LD were administered50H1N1 influenza virus liquid was administered by nasal drip, each 35. mu.L. The administration is started on the day of infection, and 20 mL/kg is given each time1And (4) performing intragastric administration for 1 time/day continuously for 4 days, and performing intragastric administration on the normal control group and the model control group by using distilled water with the same volume respectively. On the 5 th day, 10 mice were taken from each group, after weighing, the eyeballs were picked and blood was taken to measure the contents of TNF-alpha, IFN-gamma, and IL-6 in the serum, then the lung mass was dissected and weighed, and the lung index inhibition rate were calculated. The rest mice were observed for 2 weeks after infection, andanimals were observed for mortality over 2 weeks and mortality, mean survival days and life extension rate were calculated. Statistical treatment was performed using an inter-group comparison t-test.
Lung index ═ lung wet mass (g)/body mass (g)
The lung index inhibition rate is (m virus control lung-m experimental lung)/(m virus control lung-m normal control lung) x 100%
The life extension rate (test survival days-virus control survival days)/(virus control survival days) × 100%
3. Results of the experiment
(1) Effect of DHF on pulmonary index of H1N1 pneumonia-infected mice
After a normal mouse is infected by the influenza A H1N1 virus, the lung index of the mouse is obviously increased, and the lung index is obviously different from that of a normal control group (P is less than 0.01); lung indexes of 3 dose groups are reduced in different degrees after 4 days of DHF treatment, wherein DHF of the high dose group, the middle dose group and the combined drug group are remarkably different from those of a model control group (P is less than 0.05). The results are shown in Table 1.
Table 1 effect of DHF on lung index of H1N1 pneumonia-infected mice: (
n＝10)
*p<0.5,**p<0.01
(2) Influence of DHF on survival days and mortality of H1N1 pneumonia-infected mouse pneumonia model
After the H1N1 influenza A virus infects the mouse for 14d, the animal mortality rate is 90 percent, the average survival days is 8.15d, the DHF treatment time is 4d, the animal mortality rate of 3 dose groups and combination groups is obviously reduced, and the animal mortality rate is obviously reduced; the 3 dose groups can prolong the average survival days of animals, and the difference is significant compared with a model control group (P < 0.01). The results are shown in Table 2.
Table 2 effect of DHF on mortality and days to live in H1N1 pneumonia infected mice (N ═ 10)
*p<0.5,**p<0.01
(3) Effect of DHF on cytokines in serum of H1N1 pneumonia-infected mice
After the H1N1 influenza virus is infected, the contents of relevant inflammatory cytokines IFN-gamma, TNF-a and IL-6 released by macrophages in the lung of a pneumonia mouse are obviously improved. The contents of IFN-gamma, TNF-a and IL-6 were statistically reduced after treatment with high and medium doses of DHF and combination (p <0.01, p < 0.05). The application mechanism of DHF in preventing and treating influenza virus infectious pneumonia is related to the cytokine inhibiting inflammatory injury. The specific results are shown in Table 3.
TABLE 3 influence of DHF on inflammatory cytokines in H1N1 pneumonia-infected mice ((
n＝10)
*p<0.5,**p<0.01。
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations of the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (10)
1. Use of Deoxyfuconojirimycin (Deoxyfuconojirimycin) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing and/or treating pediatric pneumonia in a subject.
2. Use according to claim 1, wherein the subject is an infant and the subject is between 0 and 6 years of age.
3. The use according to claim 1, wherein said pharmaceutically acceptable salt is deoxyfucojirimycin hydrochloride (deoxyfuconoijirimycin hydrochloride).
4. The use according to any one of claims 1 to 3, wherein the pneumonia is caused by a viral infection.
5. The use according to claim 4, wherein the virus is an adenovirus, an influenza A virus, an influenza B virus, a respiratory syncytial virus, a coxsackie virus or a parainfluenza virus.
6. The use according to claim 5, wherein the virus is influenza A subtype H1N 1.
7. The use of any one of claims 1 to 6, wherein said deoxyfucose nojirimycin or a pharmaceutically acceptable salt thereof reduces the pulmonary index, reduces mortality, prolongs survival time of said subject.
8. The use of any one of claims 1 to 6, wherein said deoxyfucose nojirimycin or a pharmaceutically acceptable salt thereof inhibits the production of inflammatory factors and reduces the levels of IFN- γ, TNF- α and IL-6.
9. Use according to any one of claims 1 to 8, wherein said deoxyfucose nojirimycin or a pharmaceutically acceptable salt thereof is prepared in a pharmaceutical preparation selected from an oral preparation, a parenteral preparation, an inhalation preparation or a topical preparation, in a pharmaceutically acceptable excipient.
10. The use according to claim 9, wherein the formulation is selected from the group consisting of tablets, capsules, oral liquids, injections, powder injections, sprays, transdermal patches, emulsions, ointments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010851711.5A CN111904959A (en) | 2020-08-21 | 2020-08-21 | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010851711.5A CN111904959A (en) | 2020-08-21 | 2020-08-21 | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111904959A true CN111904959A (en) | 2020-11-10 |
Family
ID=73278962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010851711.5A Pending CN111904959A (en) | 2020-08-21 | 2020-08-21 | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111904959A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115054611A (en) * | 2022-07-19 | 2022-09-16 | 牡丹江医学院 | Medicine for treating infantile pneumonia and application thereof |
| CN115381843A (en) * | 2022-10-28 | 2022-11-25 | 四川大学华西医院 | Application of L-fucose in preparing medicine for treating respiratory system diseases |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022975A1 (en) * | 1994-02-25 | 1995-08-31 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
| WO2010029313A1 (en) * | 2008-09-11 | 2010-03-18 | Summit Corporation Plc. | Antiinfective compounds |
| CN102625796A (en) * | 2009-09-04 | 2012-08-01 | 联合治疗公司 | Methods of treating Orthomyxoviral infections |
| CN105636589A (en) * | 2013-09-16 | 2016-06-01 | 伊美根特病毒学公司 | Deoxynojirimycin derivatives and methods of their using |
| WO2017201030A1 (en) * | 2016-05-16 | 2017-11-23 | Emergent Virology Llc | Methods of treating viral infection |
-
2020
- 2020-08-21 CN CN202010851711.5A patent/CN111904959A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022975A1 (en) * | 1994-02-25 | 1995-08-31 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
| WO2010029313A1 (en) * | 2008-09-11 | 2010-03-18 | Summit Corporation Plc. | Antiinfective compounds |
| CN102625796A (en) * | 2009-09-04 | 2012-08-01 | 联合治疗公司 | Methods of treating Orthomyxoviral infections |
| CN105636589A (en) * | 2013-09-16 | 2016-06-01 | 伊美根特病毒学公司 | Deoxynojirimycin derivatives and methods of their using |
| WO2017201030A1 (en) * | 2016-05-16 | 2017-11-23 | Emergent Virology Llc | Methods of treating viral infection |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115054611A (en) * | 2022-07-19 | 2022-09-16 | 牡丹江医学院 | Medicine for treating infantile pneumonia and application thereof |
| CN115054611B (en) * | 2022-07-19 | 2023-12-29 | 牡丹江医学院 | Medicine for treating infantile pneumonia and application thereof |
| CN115381843A (en) * | 2022-10-28 | 2022-11-25 | 四川大学华西医院 | Application of L-fucose in preparing medicine for treating respiratory system diseases |
| CN115381843B (en) * | 2022-10-28 | 2023-01-10 | 四川大学华西医院 | Application of L-fucose in preparing medicine for treating respiratory system diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101706624B1 (en) | Agent for the prophylaxis and treatment of highly pathogenic infectious diseases | |
| ES2392379T3 (en) | Use of an acetylsalicylic acid salt for the treatment of viral infections | |
| CN111904959A (en) | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia | |
| CN113773275A (en) | Antiviral compound and preparation method thereof | |
| CN112694463B (en) | Application of isopentenyl chromone compound in preparation of anti-coronavirus medicines | |
| US6500808B2 (en) | Anti-viral composition | |
| CN110237074B (en) | Application of benidipine in preparation of medicine for preventing and/or treating bunidipine virus infectious diseases | |
| CN113368121A (en) | Anti-coronavirus phillyrin and phillygenin composition | |
| US11980632B2 (en) | Antiviral composition containing fucosyllactose as active ingredient | |
| US7341988B2 (en) | Method of treating influenza with geranyl-geranyl acetone | |
| WO1997037661A1 (en) | Preventive and remedy for viral infections | |
| CN112245424B (en) | Application of bisabolane sesquiterpene structural analogue in preparation of anti-coronavirus medicines | |
| CN106562970B (en) | The purposes of GS-9620 | |
| CN114762694B (en) | Use of oligosaccharide transferase inhibitors for the prevention and/or treatment of novel coronavirus infections | |
| CN112675172B (en) | Application of diketopiperazine compound in preparation of anti-coronavirus drugs | |
| CN115837026B (en) | Composition and application thereof in preparation of medicines with anti-hepatitis effect | |
| CN111568917B (en) | Application of flammulina velutipes polysaccharide extract in preparation of antiviral drugs and extraction method thereof | |
| CN113509461B (en) | Application of bilobalide composition in preparing medicine for treating or preventing coronavirus infection | |
| CN115006383B (en) | Application of diphenyl ether compound in preparation of anti-coronavirus drugs | |
| CN113274406B (en) | New application of manganese chloride or composition containing manganese chloride in preparation of drugs for treating African swine fever | |
| CN117510408A (en) | Antiviral traditional Chinese medicine monomer dauricine, pharmaceutical composition and application thereof | |
| US20230338475A1 (en) | USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection | |
| CN114099482A (en) | Application of beta-caryophyllene in preventing and treating virus infection | |
| CN117562890A (en) | Application of chromone compound in preparation of anti-coronavirus drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201110 |
|
| RJ01 | Rejection of invention patent application after publication |